Combination of Sofosbuvir-Ledipasvir and Sofosbuvir- Daclatasvir for Treatment HCV Patients in Indonesia

Combination of Sofosbuvir-Ledipasvir and Sofosbuvir- Daclatasvir for Treatment HCV Patients in Indonesia

Introduction. Direct-acting antivirals (DAAs) has been developed for treatment hepatitis C virus (HCV). Therapy of HCV using DAA has shown high sustained virologic response (SVR) and shortening duration of therapy. Sofosbuvir-ledipasvir (SOF/LDV) is fixed dose combination tablet of DAAs which reco...

Full description

Bibliographic Details
Main Authors: Andri Sanityoso Sulaiman, Irsan Hasan, Cosmas Rinaldi Adithya Lesmana, Juferdy Kurniawan, Gita Aprilicia, Yayah Nugroho, Nunuk Tri Wahyuni, Budiman Sujatmika Sulaiman
Format: Article
Language:Indonesian
Published: Department of Internal Medicine, Faculty of Medicine Universitas Indonesia 2023-12-01
Series:Jurnal Penyakit Dalam Indonesia
Subjects:
direct acting antiviral agents (daas)
hcv
sofosbuvir-daclatasvir (sof/dcv)
sofosbuvir-ledipasvir (sof/ldv)
svr-12
Online Access:https://scholarhub.ui.ac.id/jpdi/vol10/iss4/3/

Internet

https://scholarhub.ui.ac.id/jpdi/vol10/iss4/3/

Similar Items